MedTech Spectrum

Article Name Clinical & Diagnostic

GMS Announces Partnership With Lumina Imaging And Diagnostics

Group Management Services (GMS), a leading professional employer organization (PEO) headquartered in Richfield, Ohio, is pleased to announce its partnership with Lumina Imaging and Diagnostics. This collaboration revolutionizes the health care landscape for GMS clients and their employees throughout Northeast Ohio.

03rd July, 2023

BD India's Pledge for Safety Initiative Launched with a 'Safety Flame' March from Ruby Hall Clinic

To enhance awareness around the importance of safety protocols, practices, and technologies to deliver optimum Patient and clinical outcomes as well as enable knowledge-sharing of best practices around this key area, BD (Becton, Dickinson, and Company) recently organized the ‘Pledge for Safety' - Clinical Leaders Forum.

30th June, 2023

APAC Cardiovascular Disease Alliance to tackle heart disease in Asia

Building interdisciplinary, multisectoral partnerships to unite CVD action across borders

28th June, 2023

HSS Surgeon Performs World's First Stemmed Elliptical Head Prosthesis Implant for Shoulder Replacement

System Allows Conversion to Reverse Shoulder Replacement Prosthesis

28th June, 2023

Roche Gets FDA Clearance for Additional Alzheimer's CSF Assays, Enhancing Diagnosis and Treatment Decisions

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and tTau assays (used as a tTau/Abeta42 ratio) measure two biomarkers of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease.

28th June, 2023

INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day incubation clearance demonstrated improved patient outcomes.

28th June, 2023